Why metformin contraindicated in renal disease
Reading File
Finding Sources
Searching PubMed
metformin lactic acidosis renal impairment
Reading File
Reading File
Excellent - I have very detailed content from both Katzung and Goodman & Gilman. Let me now compile the full answer.
Why Metformin is Contraindicated in Renal Disease
1. Pharmacokinetic Basis - Drug Accumulation
Metformin has a unique pharmacokinetic profile that makes it vulnerable in renal impairment:
- Not metabolized - excreted entirely unchanged in the urine
- Not protein-bound - freely circulates in plasma
- Half-life is 1.5-5 hours under normal renal function
- Renal uptake is mediated by organic cation transporter type 2 (OCT2), and export into urine is via MATE1/2 (multidrug and toxin extrusion proteins)
When the kidneys fail, metformin cannot be cleared and accumulates in the body. Plasma metformin levels are inversely related to renal function.
- Katzung's Basic and Clinical Pharmacology, 16e
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
2. The Core Risk - Lactic Acidosis
Metformin accumulation raises the risk of lactic acidosis through two mechanisms:
A. Blockade of hepatic gluconeogenesis:
Metformin activates AMPK (AMP-activated protein kinase) in hepatocytes and also inhibits mitochondrial glycerol phosphate dehydrogenase, altering cellular redox state. Both actions suppress gluconeogenesis - but gluconeogenesis is the main pathway by which the liver clears lactate. When this is blocked, lactate builds up in the blood.
B. Mitochondrial inhibition:
Metformin is thought to impair oxidative phosphorylation in hepatocyte mitochondria (Complex I of the electron transport chain). This shifts cellular metabolism toward anaerobic glycolysis, generating more lactate. At high (accumulated) drug concentrations, this effect becomes clinically significant.
The combined result is metformin-associated lactic acidosis (MALA) - a high anion gap metabolic acidosis that carries significant mortality.
- Katzung: "As a consequence of metformin's blockade of gluconeogenesis, the drug may impair the hepatic metabolism of lactic acid. In patients with renal insufficiency, the biguanide accumulates and thereby increases the risk of lactic acidosis, which appears to be a dose-related complication."
- Miller's Anesthesia, 10e: "Renal impairment appears to be a significant risk factor [for MALA]."
3. eGFR-Based Thresholds (Current Guidelines)
| eGFR (mL/min/1.73 m²) | Recommendation |
|---|---|
| ≥ 60 | Safe to use |
| 45-60 | Use with caution; monitor renal function more frequently |
| 30-45 | Use cautiously (stable CKD only); consider dose reduction |
| < 30 | Contraindicated |
| End-stage renal disease / dialysis | Contraindicated |
- Katzung: "Metformin can be safely used in patients with estimated glomerular filtration rates (eGFR) between 60 and 45 mL/min per 1.73 m². It can be used cautiously in patients with stable eGFR between 45 and 30 mL/min per 1.73 m². It is contraindicated if the eGFR is less than 30 mL/min per 1.73 m²."
4. Additional Risk Factors That Compound the Problem
Even in patients with normal baseline renal function, conditions that impair renal perfusion or add to lactate production increase MALA risk:
- Congestive heart failure (reduced renal perfusion + tissue hypoxia)
- Sepsis (hypoperfusion, elevated lactate)
- Decompensated liver failure (reduced lactate clearance)
- Contrast media (risk of acute kidney injury post-procedure)
- NSAIDs (reduce renal blood flow and GFR, raising metformin concentration)
5. Is the Causal Link Certain?
Importantly, Goodman & Gilman notes a nuance: "recent analyses have raised doubts regarding whether the association of metformin with lactic acidosis is causal." Renal failure is itself a common cause of lactic acidosis independently, so some cases attributed to metformin may be lactic acidosis from the underlying illness with metformin merely present. This has led some guidelines to permit cautious use down to eGFR 30, rather than the older, stricter cutoff of eGFR 60.
Summary
| Mechanism | Consequence |
|---|---|
| Renal excretion without metabolism | Drug accumulates when GFR falls |
| Inhibits hepatic gluconeogenesis | Impairs lactate clearance by the liver |
| Inhibits mitochondrial complex I | Promotes anaerobic lactate production |
| Accumulation is dose-dependent | Risk of MALA rises steeply at eGFR < 30 |
The contraindication at eGFR < 30 mL/min/1.73 m² is well-established. Between eGFR 30-45, the drug is used cautiously with close monitoring, reflecting the balance between real lactic acidosis risk and metformin's significant cardiovascular and metabolic benefits.
Recent literature: A 2024 review (PMID 38983827) confirms that renal impairment remains the dominant risk factor for MALA in critically ill patients, supporting the current eGFR-based thresholds.
Give short and exact imp point answers in points
Metformin Contraindicated in Renal Disease - Key Points
Pharmacokinetics:
- Excreted unchanged by kidneys (not metabolized)
- Not protein-bound → freely accumulates
- In renal failure → drug accumulates → toxic plasma levels
Core Risk - Lactic Acidosis:
- Metformin blocks hepatic gluconeogenesis → liver cannot clear lactate
- Inhibits mitochondrial Complex I → shifts metabolism to anaerobic → more lactate produced
- Result = Metformin-Associated Lactic Acidosis (MALA) - high mortality
eGFR Thresholds:
- eGFR > 60 → Safe
- eGFR 45-60 → Caution + monitor
- eGFR 30-45 → Use cautiously (stable CKD only)
- eGFR < 30 → Contraindicated
Other conditions that also contraindicate/require caution:
- Decompensated liver failure (impaired lactate clearance)
- Heart failure (tissue hypoxia + poor renal perfusion)
- Sepsis (hypoperfusion)
- Pre-contrast media administration (risk of acute kidney injury)
- NSAIDs co-use (reduce GFR → raise metformin levels)
One-line summary:
Metformin accumulates in renal failure → blocks lactate clearance + promotes lactate production → lactic acidosis
Include enzyme name they are imp for exams
Metformin in Renal Disease - With Enzymes (Exam Focus)
Mechanism of Action (Enzymes):
- Activates AMPK (AMP-activated protein kinase) → suppresses hepatic gluconeogenesis
- Inhibits mitochondrial Complex I (NADH dehydrogenase) → blocks oxidative phosphorylation → anaerobic glycolysis → ↑ lactate
- Inhibits mitochondrial glycerol-3-phosphate dehydrogenase (mGPD) → alters hepatic redox state (↑ NADH/NAD⁺ ratio) → lactate cannot be converted to pyruvate
Why Lactic Acidosis in Renal Failure:
| Step | Enzyme Involved | Result |
|---|---|---|
| Blocks gluconeogenesis | AMPK activation | Liver can't clear lactate |
| Blocks mitochondrial respiration | Complex I (NADH dehydrogenase) | More lactate produced |
| Alters redox state | mGPD inhibition | ↑ NADH → lactate accumulates |
| Drug accumulates | No enzyme (renal excretion fails) | All above effects amplified |
Transport Enzymes (Exam-worthy):
- Enters hepatocytes via OCT1 (Organic Cation Transporter 1)
- Renal uptake via OCT2 (Organic Cation Transporter 2)
- Excreted into urine via MATE1/MATE2 (Multidrug And Toxin Extrusion proteins)
- In renal failure → OCT2/MATE1/2 fail → drug trapped → accumulation
eGFR Cutoffs (Exam High-Yield):
- < 30 mL/min/1.73 m² → Contraindicated
- 30-45 → Cautious use only
- 45-60 → Monitor closely
-
60 → Safe
One-liner for exam:
Metformin inhibits Complex I and mGPD → ↑ lactate; in renal failure, OCT2/MATE transport fails → accumulation → fatal lactic acidosis
Compare metformin with other biguanides (phenformin, buformin)
Finding Sources
Finding Sources
Reading File
Reading File
Biguanides Comparison: Metformin vs Phenformin vs Buformin
Quick Status
| Drug | Status | Reason |
|---|---|---|
| Metformin | ✅ Only one in use | Acceptable safety profile |
| Phenformin | ❌ Withdrawn 1976-78 | Unacceptably high lactic acidosis rate |
| Buformin | ❌ Withdrawn 1970s | Same - unacceptable lactic acidosis |
Detailed Comparison (Exam Points)
| Feature | Metformin | Phenformin | Buformin |
|---|---|---|---|
| Class | Biguanide | Biguanide | Biguanide |
| Current use | Yes (1st line T2DM) | No - withdrawn | No - withdrawn |
| Lipid solubility | Low | High | High |
| Mitochondrial membrane penetration | Limited | High | High |
| Complex I inhibition | Mild/moderate | Severe | Severe |
| Lactic acidosis risk | Low (rare) | Very high | Very high |
| Metabolism | Not metabolized | Hepatically metabolized | Hepatically metabolized |
| Excretion | Renal (unchanged) | Renal + hepatic | Renal + hepatic |
| Protein binding | None | Yes | Yes |
Key Enzyme - Why Phenformin is Worse (Exam Critical)
- All biguanides inhibit mitochondrial Complex I (NADH dehydrogenase)
- Phenformin/buformin = highly lipid soluble → easily cross mitochondrial membrane → bind Complex I more avidly → greater inhibition → more anaerobic glycolysis → far more lactate
- Metformin = low lipid solubility → limited mitochondrial membrane crossing → weaker Complex I binding → much lower lactic acidosis risk
"Metformin has a markedly lower incidence of lactic acidosis than phenformin, possibly because it is less lipid soluble and thus has limited ability to cross the mitochondrial membrane and bind to mitochondrial complex." - NKF Primer on Kidney Diseases, 8e
Why Phenformin Was Withdrawn - Key Facts
- Lactic acidosis incidence with phenformin: ~40-64 cases per 100,000 patient-years
- Lactic acidosis with metformin: ~3-5 cases per 100,000 patient-years (much rarer)
- Phenformin withdrawn from USA in 1976, UK/Europe by 1978
- Buformin withdrawn around the same period for identical reasons
Common Mechanism (All Biguanides)
All three work via:
- Activate AMPK → suppress gluconeogenesis
- Inhibit Complex I (NADH dehydrogenase) → reduce ATP → impair oxidative phosphorylation
- Inhibit mGPD (mitochondrial glycerol-3-phosphate dehydrogenase) → alter NADH/NAD⁺ ratio → impair lactate clearance
One-liner for Exam
Phenformin and buformin are highly lipid soluble → cross mitochondrial membrane freely → inhibit Complex I severely → cause fatal lactic acidosis → withdrawn in 1970s; Metformin's low lipid solubility limits this → still in use today
moa of combined oral contraceptive pills
Finding Sources
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
I now have all the content needed from Harrison's and Goldman-Cecil. Here is the complete answer:
MOA of Combined Oral Contraceptive Pills (COCP)
Components
- Estrogen - Ethinyl estradiol (EE), 20-35 µg
- Progestin - Levonorgestrel, norethindrone, drospirenone, desogestrel, norgestimate (varies by formulation)
Mechanisms (Multiple Levels - All Exam-Important)
1. Suppression of Ovulation (PRIMARY mechanism)
Estrogen component:
- Continuous estrogen → negative feedback on hypothalamus → ↓ GnRH pulsatility
- → ↓ FSH secretion from anterior pituitary
- → No follicular development → no dominant follicle formed
- → No estrogen surge → no LH surge → ovulation blocked
Progestin component:
- Suppresses LH secretion directly at pituitary level
- Prevents the mid-cycle LH surge → ovulation cannot occur
"Negative feedback from continuous estrogen administration decreases FSH secretion, follicular development, and formation of a dominant follicle. Continuous progestin suppresses LH secretion and inhibits ovulation." - Harrison's Principles, 22e
2. Thickening of Cervical Mucus (Progestin effect)
- Progestin → cervical mucus becomes thick, viscous, scanty
- Hostile to sperm penetration
- Sperm cannot reach the egg even if ovulation occurs (backup mechanism)
3. Endometrial Changes (Progestin effect)
- Progestin → endometrium becomes thin, atrophic, out of phase
- Glands and stroma become unreceptive
- Even if fertilization occurs, implantation is impaired
4. Impaired Tubal Motility (Progestin effect)
- Progestin reduces fallopian tube peristalsis
- Slows ovum transport
- Reduces chance of sperm-ovum meeting
5. Suppression of Ovarian Androgen Synthesis (Estrogen effect - bonus)
- Estrogen → ↑ SHBG (Sex Hormone Binding Globulin) in liver
- More androgens bound → less free testosterone → anti-androgenic effect
- Useful in PCOS, acne, hirsutism
Summary Table
| Mechanism | Component Responsible | Target |
|---|---|---|
| ↓ FSH → no follicle development | Estrogen | Hypothalamus-pituitary |
| ↓ LH surge → no ovulation | Progestin (+ estrogen) | Anterior pituitary |
| Thick cervical mucus | Progestin | Cervix |
| Atrophic endometrium | Progestin | Uterus |
| Impaired tubal motility | Progestin | Fallopian tube |
| ↑ SHBG → ↓ free androgen | Estrogen | Liver |
Efficacy
- Failure rate: ~8 pregnancies per 100 women/year (typical use)
- With perfect use: < 1%
- Primary mechanism = ovulation suppression (most reliable)
- Backup mechanisms = cervical mucus + endometrium (if ovulation breakthrough occurs)
One-liner for Exam
COCP: Estrogen suppresses FSH (no follicle) + Progestin suppresses LH (no ovulation) + thickens cervical mucus + renders endometrium hostile + impairs tubal motility
- Harrison's Principles of Internal Medicine, 22e
- Goldman-Cecil Medicine, International Edition
This is a shared conversation. Sign in to Orris to start your own chat.